Clinical Trials Directory

Trials / Completed

CompletedNCT02133469

PCV7 in the Prevention of Nasopharyngeal Carriage of Vaccine Serotype (VT) Streptococcus Pneumoniae

Effectiveness of PCV7 in the Prevention of Nasopharyngeal Carriage of Vaccine Serotype (VT) Streptococcus Pneumoniae in 2 to 5 Years Old Healthy Chinese Children.

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
3,281 (actual)
Sponsor
Centers for Disease Control and Prevention, China · Other Government
Sex
All
Age
2 Years – 5 Years
Healthy volunteers
Accepted

Summary

A parallel-group, randomized, open-label study will be performed in subjects receiving PCV7 and subjects receiving controlled vaccine Hib vaccine, to claim the efficacy of PCV7 in the prevention of NP carriage of vaccine-serotype S. pneumoniae (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F combined) in 2 to 5 years old healthy Chinese children.

Detailed description

In 2005, clinical trials with PCV7 (Prevenar) were first conducted in China. In the phase 3 study involving Chinese infants, Prevenar was shown to be immunogenic, well tolerated, and safe when given either separately or concomitantly with a diphtheria, tetanus, and acellular pertussis (DTaP) vaccine at 3, 4, and 5 months of age. Controlled clinical trials elsewhere in the world showed the correlation between immunogenicity and disease prevention. In addition to the direct effect of Prevenar, immunization of children has also reduced the incidence of disease in adults. The changes are presumed to be due to reductions in nasopharyngeal carriage of vaccine serotype S. pneumoniae in children who have been vaccinated. The purpose of this study will be to assess the effectiveness of Prevenar vaccination to reduce vaccine serotype (VT) NPC rates in Chinese children aged 2 to 5 years old.

Conditions

Interventions

TypeNameDescription
BIOLOGICALPCV7 (Pneumococcal 7-Valent Conjugate Vaccine)injection 0.5 mL, single dose
BIOLOGICALHib VaccineSingle Dose

Timeline

Start date
2012-06-01
Primary completion
2014-04-01
Completion
2014-05-01
First posted
2014-05-08
Last updated
2016-05-20

Locations

9 sites across 1 country: China

Source: ClinicalTrials.gov record NCT02133469. Inclusion in this directory is not an endorsement.